Sugi Predict

Sugi Predict / Targets / MAG

MAG

Myelin-associated glycoprotein · P20916 · MAG on Sugi Atlas →

6,362 patent compounds predicted against MAG, 4,142 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12341412 SCHEMBL12341412 0.51 15/20
SCHEMBL12341411 SCHEMBL12341411 0.51 15/20
SCHEMBL12341427 SCHEMBL12341427 0.55 13/20
SCHEMBL12341410 SCHEMBL12341410 0.50 13/20
SCHEMBL8673965 SCHEMBL8673965 0.62 12/20
SCHEMBL13082543 SCHEMBL13082543 0.52 12/20
SCHEMBL11962138 SCHEMBL11962138 0.50 12/20
SCHEMBL12681616 SCHEMBL12681616 0.70 11/20
SCHEMBL12898683 SCHEMBL12898683 0.64 11/20
SCHEMBL12138042 SCHEMBL12138042 0.58 11/20
SCHEMBL12313944 SCHEMBL12313944 0.56 11/20
SCHEMBL12130155 SCHEMBL12130155 0.55 11/20
SCHEMBL11962136 SCHEMBL11962136 0.54 11/20
SCHEMBL12130156 SCHEMBL12130156 0.53 11/20
SCHEMBL12130153 SCHEMBL12130153 0.53 11/20
SCHEMBL11962144 SCHEMBL11962144 0.53 11/20
SCHEMBL12199667 SCHEMBL12199667 0.52 11/20
SCHEMBL12130152 SCHEMBL12130152 0.52 11/20
SCHEMBL12130154 SCHEMBL12130154 0.52 11/20
SCHEMBL14749206 SCHEMBL14749206 0.45 11/20

Clinical trials — most relevant to MAG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders PHASE3RECRUITING
Intravenous Immunoglobulin Therapy in Optic Neuritis PHASE3COMPLETED
Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease PHASE2/PHASE3ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD) PHASE3ACTIVE_NOT_RECRUITING
Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy PHASE2ACTIVE_NOT_RECRUITING
AXER-204 in Participants With Chronic Spinal Cord Injury PHASE1/PHASE2COMPLETED
Safety Escalating Repeat IV, in Stroke Patients PHASE2COMPLETED
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study PHASE2COMPLETED
A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies PHASE2UNKNOWN
Fingolimod in Schizophrenia Patients PHASE2COMPLETED
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients PHASE2COMPLETED
Anti-MAG First Administration to Human PHASE1COMPLETED
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases EARLY_PHASE1NOT_YET_RECRUITING
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases EARLY_PHASE1RECRUITING
Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus nanUNKNOWN
Initial Clinical Presentation of Inflammatory Optic Neuritis Associated or Not With Autoantibodies Anti-Myelin-oligodendrocyte-glycoprotein nanCOMPLETED
Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis nanCOMPLETED
Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected nanRECRUITING
The Clinical Features of Combined Central and Peripheral Demyelination nanUNKNOWN
Immunologic Biomarker Profile of Cerebrospinal Fluid nanCOMPLETED
sCD163 as a Potential Biomarker in Guillain- Barré Syndrome nanUNKNOWN
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital nanCOMPLETED
Headache Prevalence and Phenotype in Myelin Oligodendrocyte Glycoprotein Antibody -Associated Disease (MOGAD) nanNOT_YET_RECRUITING
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients nanCOMPLETED
The Myelin Disorders Biorepository Project nanRECRUITING
Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM) nanNOT_YET_RECRUITING
Application of ihMT MRI in Multiple Sclerosis nanRECRUITING
Immunoglobulin M (IgM)-Anti-myelin-associated-glycoprotein(MAG) Peripheral Neuropathy Study nanRECRUITING
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients nanCOMPLETED
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAG binder may also engage these)

ProteinNameSimilarity
P20917 — 1.000 P20917 →
P07722 — 1.000 P07722 →
Q1WIM1 — 0.969 Q1WIM1 →
ICOSLG ICOS ligand 0.968 landscape →
PDCD1LG2 Programmed cell death 1 ligand 2 0.965 landscape →
Q8NFZ8 — 0.965 Q8NFZ8 →
Q15223 — 0.964 Q15223 →
Q9GL76 — 0.963 Q9GL76 →
NECTIN4 Nectin-4 0.963 landscape →
Q9JKF6 — 0.962 Q9JKF6 →
P15151 — 0.962 P15151 →
Q8R007 — 0.961 Q8R007 →
Q8R464 — 0.961 Q8R464 →
O18796 — 0.960 O18796 →
Q5E9Z9 — 0.960 Q5E9Z9 →
P32506 — 0.959 P32506 →
Q6AYP5 — 0.958 Q6AYP5 →
Q9WUL5 — 0.957 Q9WUL5 →
Q9Z109 — 0.956 Q9Z109 →
Q8BQC3 — 0.955 Q8BQC3 →
Q96MU8 — 0.954 Q96MU8 →
P38484 — 0.951 P38484 →
Q8IVU1 — 0.951 Q8IVU1 →
O75054 — 0.951 O75054 →
Q92692 — 0.951 Q92692 →
Q96IQ7 — 0.950 Q96IQ7 →
Q6QNK2 — 0.950 Q6QNK2 →
P32942 — 0.950 P32942 →
Q9BY67 — 0.949 Q9BY67 →
Q9P2J2 — 0.949 Q9P2J2 →